Drug profile · INN
rasagiline
ALZIRAS
rasagiline (ALZIRAS) is a monoamine oxidase b inhibitor. Associated with Lacuna Pharma Pty Ltd.
Drug details — rasagiline
- Class
- Nervous system (N04)
- Route
- —
- Patents
- 12
- Programs
- 10
- Data quality
- 0.89
Quick answer
rasagiline (ALZIRAS) is a monoamine oxidase b inhibitor. Associated with Lacuna Pharma Pty Ltd.
Key facts
Mechanism of action
Monoamine oxidase B inhibitor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12310929
Use of rasagiline for the treatment of restless legs syndrome
granted -
US 9308182
Parenteral formulations of rasagiline
granted -
US 8809310
Use of rasagiline for the treatment of multiple system atrophy
granted -
US 8691872
Dispersions of rasagiline citrate
granted -
US 8569379
Use of rasagiline for the treatment of olfactory dysfunction
granted -
US 8080584
Delayed release rasagiline citrate formulation
granted -
US 7855233
Citrate salt of Rasagiline
granted -
US 7815942
Rasagiline formulations of improved content uniformity
granted -
US 7619117
Rasagiline formulations and processes for their preparation
granted -
US 7598420
Rasagiline formulations and processes for their preparation
granted -
US 7572834
Rasagiline formulations and processes for their preparation
granted -
US 7547806
Tannate salt of rasagiline
granted
Frequently asked questions
What is rasagiline?
rasagiline (ALZIRAS) is a monoamine oxidase b inhibitor. Associated with Lacuna Pharma Pty Ltd.
What is the brand name for rasagiline?
ALZIRAS is a marketed brand name for rasagiline. Check FDA Drugs@FDA for the current US label holder and prescribing information.